首页 > 最新文献

European urology focus最新文献

英文 中文
Data Availability Statements and Data Sharing in Urology: A False Promise? 泌尿外科的数据可用性声明和数据共享:虚假承诺?
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-04 DOI: 10.1016/j.euf.2024.05.019
Maria Giovanna Asmundo, Emil Durukan, Giorgio Ivan Russo, Christian Fuglesang S Jensen, Peter Busch Østergren, Sebastiano Cimino, Mikkel Fode

Background and objective: It is considered standard for authors of scientific papers to provide access to their raw data. The purpose of this study was to investigate data availability statements (DAS) and the actual availability of data in urology.

Methods: The DAS policies of the top ten urology journals were retrieved. Then 190 selected papers were classified according to their DAS status. Finally, we contacted the corresponding authors of papers that stated that data were available on request to enquire about this possibility.

Key findings and limitations: All journals either required or highly recommended a DAS. Among the selected articles, 52% (99/190) included a DAS stating data availability, most often on reasonable request to the corresponding author. A formal DAS was lacking in 29.5% (56/190) of the articles, with an additional 18.3% (35/190) citing various reasons for data unavailability. On contact, 23.4% (15/64) of corresponding authors indicated a willingness to share their data. Overall, data were unavailable in 73.7% (140/190) of cases. There was no difference between papers dealing with malignant and benign diseases.

Conclusions and clinical implications: There is a gap between the intention to share data and actual practice in major urological journals. As data sharing plays a critical role in safeguarding the reliability of published results and in the potential for reanalysis and merging of datasets, there is a clear need for improvement. Easier access to data repositories and stronger enforcement of existing journal policies are essential.

Patient summary: To ensure the reliability of data and allow further analyses, major urology journals require authors to make their data available to other researchers when possible. However, in practice we found that data were only accessible for about a quarter of published scientific papers.

背景和目的:科学论文的作者提供原始数据是一项标准要求。本研究旨在调查数据可用性声明(DAS)和泌尿科数据的实际可用性:方法:检索了排名前十的泌尿学期刊的 DAS 政策。方法:我们检索了排名前十的泌尿外科期刊的数据可用性声明(DAS)政策,然后根据其 DAS 状态对 190 篇选定论文进行了分类。最后,我们联系了声明可应要求提供数据的论文的通讯作者,询问这种可能性:所有期刊都要求或强烈推荐DAS。在所选文章中,52%(99/190)的文章包含了DAS,说明了数据的可用性,最常见的情况是向通讯作者提出合理要求。29.5%(56/190)的文章未提供正式的 DAS,另有 18.3%(35/190)的文章以各种理由说明数据不可用。经联系,23.4%(15/64)的通讯作者表示愿意共享数据。总体而言,73.7%(140/190)的论文无法提供数据。涉及恶性和良性疾病的论文之间没有差异:结论与临床意义:主要泌尿外科期刊共享数据的意愿与实际做法之间存在差距。由于数据共享在保障发表结果的可靠性以及重新分析和合并数据集的可能性方面发挥着至关重要的作用,因此显然有必要加以改进。患者摘要:为了确保数据的可靠性并允许进一步分析,主要泌尿学期刊要求作者在可能的情况下向其他研究人员提供数据。然而,在实践中,我们发现仅有约四分之一的已发表科学论文可以获取数据。
{"title":"Data Availability Statements and Data Sharing in Urology: A False Promise?","authors":"Maria Giovanna Asmundo, Emil Durukan, Giorgio Ivan Russo, Christian Fuglesang S Jensen, Peter Busch Østergren, Sebastiano Cimino, Mikkel Fode","doi":"10.1016/j.euf.2024.05.019","DOIUrl":"10.1016/j.euf.2024.05.019","url":null,"abstract":"<p><strong>Background and objective: </strong>It is considered standard for authors of scientific papers to provide access to their raw data. The purpose of this study was to investigate data availability statements (DAS) and the actual availability of data in urology.</p><p><strong>Methods: </strong>The DAS policies of the top ten urology journals were retrieved. Then 190 selected papers were classified according to their DAS status. Finally, we contacted the corresponding authors of papers that stated that data were available on request to enquire about this possibility.</p><p><strong>Key findings and limitations: </strong>All journals either required or highly recommended a DAS. Among the selected articles, 52% (99/190) included a DAS stating data availability, most often on reasonable request to the corresponding author. A formal DAS was lacking in 29.5% (56/190) of the articles, with an additional 18.3% (35/190) citing various reasons for data unavailability. On contact, 23.4% (15/64) of corresponding authors indicated a willingness to share their data. Overall, data were unavailable in 73.7% (140/190) of cases. There was no difference between papers dealing with malignant and benign diseases.</p><p><strong>Conclusions and clinical implications: </strong>There is a gap between the intention to share data and actual practice in major urological journals. As data sharing plays a critical role in safeguarding the reliability of published results and in the potential for reanalysis and merging of datasets, there is a clear need for improvement. Easier access to data repositories and stronger enforcement of existing journal policies are essential.</p><p><strong>Patient summary: </strong>To ensure the reliability of data and allow further analyses, major urology journals require authors to make their data available to other researchers when possible. However, in practice we found that data were only accessible for about a quarter of published scientific papers.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"999-1002"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Wei He, Shuxiong Zeng, and Chuanliang Xu's Letter to the Editor re: Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial. Eur Urol 2024;85:422-30. 回复何伟、曾树雄、徐传亮致编辑的信:Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. 机器人辅助根治性膀胱切除术与完全体外尿路转流术对比开放式根治性膀胱切除术:一项随机对照试验的 3 年结果。欧洲泌尿外科杂志》2024;85:422-30。
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-15 DOI: 10.1016/j.euf.2024.06.002
Riccardo Mastroianni, Giuseppe Chiacchio, Giuseppe Simone
{"title":"Reply to Wei He, Shuxiong Zeng, and Chuanliang Xu's Letter to the Editor re: Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial. Eur Urol 2024;85:422-30.","authors":"Riccardo Mastroianni, Giuseppe Chiacchio, Giuseppe Simone","doi":"10.1016/j.euf.2024.06.002","DOIUrl":"10.1016/j.euf.2024.06.002","url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1068-1069"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract Cancer. 针对因疑似尿路癌转诊至二级医疗机构的血尿患者的 IDENTIFY 风险计算器的机器学习和外部验证。
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-21 DOI: 10.1016/j.euf.2024.06.004
Sinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, Alexander Light, Simona Ippoliti, Marie Edison, Cameron Alexander, Meghana Kulkarni, Eleanor Zimmermann, Arjun Nathan, Luca Orecchia, Ravi Banthia, Pietro Piazza, David Mak, Nikolaos Pyrgidis, Prabhat Narayan, Pablo Abad Lopez, Faisal Nawaz, Trung-Thanh Tran, Francesco Claps, Donnacha Hogan, Juan Gomez Rivas, Santiago Alonso, Ijeoma Chibuzo, Beatriz Gutierrez Hidalgo, Jessica Whitburn, Jeremy Teoh, Gautier Marcq, Alexandra Szostek, Jasper Bondad, Petros Sountoulides, Tom Kelsey, Veeru Kasivisvanathan

Background: The IDENTIFY study developed a model to predict urinary tract cancer using patient characteristics from a large multicentre, international cohort of patients referred with haematuria. In addition to calculating an individual's cancer risk, it proposes thresholds to stratify them into very-low-risk (<1%), low-risk (1-<5%), intermediate-risk (5-<20%), and high-risk (≥20%) groups.

Objective: To externally validate the IDENTIFY haematuria risk calculator and compare traditional regression with machine learning algorithms.

Design, setting, and participants: Prospective data were collected on patients referred to secondary care with new haematuria. Data were collected for patient variables included in the IDENTIFY risk calculator, cancer outcome, and TNM staging. Machine learning methods were used to evaluate whether better models than those developed with traditional regression methods existed.

Outcome measurements and statistical analysis: The area under the receiver operating characteristic curve (AUC) for the detection of urinary tract cancer, calibration coefficient, calibration in the large (CITL), and Brier score were determined.

Results and limitations: There were 3582 patients in the validation cohort. The development and validation cohorts were well matched. The AUC of the IDENTIFY risk calculator on the validation cohort was 0.78. This improved to 0.80 on a subanalysis of urothelial cancer prevalent countries alone, with a calibration slope of 1.04, CITL of 0.24, and Brier score of 0.14. The best machine learning model was Random Forest, which achieved an AUC of 0.76 on the validation cohort. There were no cancers stratified to the very-low-risk group in the validation cohort. Most cancers were stratified to the intermediate- and high-risk groups, with more aggressive cancers in higher-risk groups.

Conclusions: The IDENTIFY risk calculator performed well at predicting cancer in patients referred with haematuria on external validation. This tool can be used by urologists to better counsel patients on their cancer risks, to prioritise diagnostic resources on appropriate patients, and to avoid unnecessary invasive procedures in those with a very low risk of cancer.

Patient summary: We previously developed a calculator that predicts patients' risk of cancer when they have blood in their urine, based on their personal characteristics. We have validated this risk calculator, by testing it on a separate group of patients to ensure that it works as expected. Most patients found to have cancer tended to be in the higher-risk groups and had more aggressive types of cancer with a higher risk. This tool can be used by clinicians to fast-track high-risk patients based on the calculator and investigate them more thoroughly.

研究背景IDENTIFY 研究利用大型多中心国际队列中血尿转诊患者的特征,建立了一个预测尿路癌的模型。除了计算个人的癌症风险外,该模型还提出了将个人划分为极低风险人群的阈值:从外部验证 IDENTIFY 血尿风险计算器,并比较传统回归与机器学习算法:对转诊至二级医疗机构的新发血尿患者进行前瞻性数据收集。收集的数据包括 IDENTIFY 风险计算器中的患者变量、癌症结果和 TNM 分期。结果测量和统计分析:结果测量和统计分析:确定了尿路癌检测的接收者操作特征曲线下面积(AUC)、校准系数、大样本校准(CITL)和布赖尔评分:验证队列中有 3582 名患者。开发队列和验证队列匹配良好。在验证队列中,IDENTIFY 风险计算器的 AUC 为 0.78。在仅对尿路癌流行国家进行的子分析中,其AUC提高到0.80,校准斜率为1.04,CITL为0.24,Brier评分为0.14。最佳机器学习模型是随机森林模型,其验证队列的AUC为0.76。在验证队列中,没有癌症被分层为极低风险组。大多数癌症被分层为中高风险组,高风险组中的癌症更具侵袭性:IDENTIFY风险计算器在预测因血尿转诊患者的癌症方面表现良好。泌尿科医生可利用该工具更好地为患者提供癌症风险咨询,将诊断资源优先用于合适的患者,并避免对癌症风险极低的患者进行不必要的侵入性手术。患者摘要:我们之前开发了一种计算器,可根据患者的个人特征预测血尿患者的癌症风险。我们对这一风险计算器进行了验证,并在另一组患者身上进行了测试,以确保它能发挥预期的作用。大多数被发现患有癌症的患者往往属于高危人群,他们所患的癌症类型更具侵袭性,风险更高。临床医生可以利用这一工具,根据计算器快速追踪高风险患者,并对他们进行更彻底的调查。
{"title":"Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract Cancer.","authors":"Sinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, Alexander Light, Simona Ippoliti, Marie Edison, Cameron Alexander, Meghana Kulkarni, Eleanor Zimmermann, Arjun Nathan, Luca Orecchia, Ravi Banthia, Pietro Piazza, David Mak, Nikolaos Pyrgidis, Prabhat Narayan, Pablo Abad Lopez, Faisal Nawaz, Trung-Thanh Tran, Francesco Claps, Donnacha Hogan, Juan Gomez Rivas, Santiago Alonso, Ijeoma Chibuzo, Beatriz Gutierrez Hidalgo, Jessica Whitburn, Jeremy Teoh, Gautier Marcq, Alexandra Szostek, Jasper Bondad, Petros Sountoulides, Tom Kelsey, Veeru Kasivisvanathan","doi":"10.1016/j.euf.2024.06.004","DOIUrl":"10.1016/j.euf.2024.06.004","url":null,"abstract":"<p><strong>Background: </strong>The IDENTIFY study developed a model to predict urinary tract cancer using patient characteristics from a large multicentre, international cohort of patients referred with haematuria. In addition to calculating an individual's cancer risk, it proposes thresholds to stratify them into very-low-risk (<1%), low-risk (1-<5%), intermediate-risk (5-<20%), and high-risk (≥20%) groups.</p><p><strong>Objective: </strong>To externally validate the IDENTIFY haematuria risk calculator and compare traditional regression with machine learning algorithms.</p><p><strong>Design, setting, and participants: </strong>Prospective data were collected on patients referred to secondary care with new haematuria. Data were collected for patient variables included in the IDENTIFY risk calculator, cancer outcome, and TNM staging. Machine learning methods were used to evaluate whether better models than those developed with traditional regression methods existed.</p><p><strong>Outcome measurements and statistical analysis: </strong>The area under the receiver operating characteristic curve (AUC) for the detection of urinary tract cancer, calibration coefficient, calibration in the large (CITL), and Brier score were determined.</p><p><strong>Results and limitations: </strong>There were 3582 patients in the validation cohort. The development and validation cohorts were well matched. The AUC of the IDENTIFY risk calculator on the validation cohort was 0.78. This improved to 0.80 on a subanalysis of urothelial cancer prevalent countries alone, with a calibration slope of 1.04, CITL of 0.24, and Brier score of 0.14. The best machine learning model was Random Forest, which achieved an AUC of 0.76 on the validation cohort. There were no cancers stratified to the very-low-risk group in the validation cohort. Most cancers were stratified to the intermediate- and high-risk groups, with more aggressive cancers in higher-risk groups.</p><p><strong>Conclusions: </strong>The IDENTIFY risk calculator performed well at predicting cancer in patients referred with haematuria on external validation. This tool can be used by urologists to better counsel patients on their cancer risks, to prioritise diagnostic resources on appropriate patients, and to avoid unnecessary invasive procedures in those with a very low risk of cancer.</p><p><strong>Patient summary: </strong>We previously developed a calculator that predicts patients' risk of cancer when they have blood in their urine, based on their personal characteristics. We have validated this risk calculator, by testing it on a separate group of patients to ensure that it works as expected. Most patients found to have cancer tended to be in the higher-risk groups and had more aggressive types of cancer with a higher risk. This tool can be used by clinicians to fast-track high-risk patients based on the calculator and investigate them more thoroughly.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1034-1042"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Readability Assessment of Patient Education Materials on Uro-oncological Diseases Using Automated Measures. 使用自动测量方法评估泌尿肿瘤疾病患者教育材料的可读性。
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-23 DOI: 10.1016/j.euf.2024.06.012
Severin Rodler, Serena Maruccia, Andre Abreu, Declan Murphy, David Canes, Stacy Loeb, Rena D Malik, Aditya Bagrodia, Giovanni E Cacciamani

Background and objective: Readability of patient education materials is of utmost importance to ensure understandability and dissemination of health care information in uro-oncology. We aimed to investigate the readability of the official patient education materials of the European Association of Urology (EAU) and American Urology Association (AUA).

Methods: Patient education materials for prostate, bladder, kidney, testicular, penile, and urethral cancers were retrieved from the respective organizations. Readability was assessed via the WebFX online tool for Flesch Kincaid Reading Ease Score (FRES) and for reading grade levels by Flesch Kincaid Grade Level (FKGL), Gunning Fog Score (GFS), Smog Index (SI), Coleman Liau Index (CLI), and Automated Readability Index (ARI). Layperson readability was defined as a FRES of ≥70 and with the other readability indexes <7 according to European Union recommendations. This study assessed only objective readability and no other metrics such as understandability.

Key findings and limitations: Most patient education materials failed to meet the recommended threshold for laypersons. The mean readability for EAU patient education material was as follows: FRES 50.9 (standard error [SE]: 3.0), and FKGL, GFS, SI, CLI, and ARI all with scores ≥7. The mean readability for AUA patient material was as follows: FRES 64.0 (SE: 1.4), with all of FKGL, GFS, SI, and ARI scoring ≥7 readability. Only 13 out of 70 (18.6%) patient education materials' paragraphs met the readability requirements. The mean readability for bladder cancer patient education materials was the lowest, with a FRES of 36.7 (SE: 4.1).

Conclusions and clinical implications: Patient education materials from leading urological associations reveal readability levels beyond the recommended thresholds for laypersons and may not be understood easily by patients. There is a future need for more patient-friendly reading materials.

Patient summary: This study checked whether health information about different cancers was easy to read. Most of it was too hard for patients to understand.

背景和目的:患者教育材料的可读性对于确保泌尿肿瘤学医疗信息的可理解性和传播至关重要。我们旨在调查欧洲泌尿学协会(EAU)和美国泌尿学协会(AUA)官方患者教育材料的可读性:方法:我们从相关组织检索了有关前列腺癌、膀胱癌、肾癌、睾丸癌、阴茎癌和尿道癌的患者教育材料。通过 WebFX 在线工具对可读性进行评估,包括弗莱什-金凯德阅读容易程度评分(FRES)和弗莱什-金凯德阅读等级评分(FKGL)、古宁雾度评分(GFS)、烟雾指数(SI)、科尔曼-廖指数(CLI)和自动可读性指数(ARI)。外行人可读性的定义是 FRES ≥70,并具有其他可读性指数 主要发现和局限性:大多数患者教育材料都未达到建议的非专业人士阈值。EAU患者教育材料的平均可读性如下:FRES 50.9(标准误差 [SE]:3.0),FKGL、GFS、SI、CLI 和 ARI 的得分均≥7。友达病人资料的平均可读性如下:FRES为64.0(SE:1.4),FKGL、GFS、SI和ARI的可读性均≥7分。在 70 份患者教育材料中,只有 13 段(18.6%)符合可读性要求。膀胱癌患者教育材料的平均可读性最低,FRES 为 36.7(SE:4.1):结论和临床意义:主要泌尿科协会提供的患者教育材料显示出的可读性水平超出了建议的非专业人士阈值,患者可能不容易理解。患者总结:这项研究检查了有关不同癌症的健康信息是否易于阅读。大部分信息对患者来说都太难理解。
{"title":"Readability Assessment of Patient Education Materials on Uro-oncological Diseases Using Automated Measures.","authors":"Severin Rodler, Serena Maruccia, Andre Abreu, Declan Murphy, David Canes, Stacy Loeb, Rena D Malik, Aditya Bagrodia, Giovanni E Cacciamani","doi":"10.1016/j.euf.2024.06.012","DOIUrl":"10.1016/j.euf.2024.06.012","url":null,"abstract":"<p><strong>Background and objective: </strong>Readability of patient education materials is of utmost importance to ensure understandability and dissemination of health care information in uro-oncology. We aimed to investigate the readability of the official patient education materials of the European Association of Urology (EAU) and American Urology Association (AUA).</p><p><strong>Methods: </strong>Patient education materials for prostate, bladder, kidney, testicular, penile, and urethral cancers were retrieved from the respective organizations. Readability was assessed via the WebFX online tool for Flesch Kincaid Reading Ease Score (FRES) and for reading grade levels by Flesch Kincaid Grade Level (FKGL), Gunning Fog Score (GFS), Smog Index (SI), Coleman Liau Index (CLI), and Automated Readability Index (ARI). Layperson readability was defined as a FRES of ≥70 and with the other readability indexes <7 according to European Union recommendations. This study assessed only objective readability and no other metrics such as understandability.</p><p><strong>Key findings and limitations: </strong>Most patient education materials failed to meet the recommended threshold for laypersons. The mean readability for EAU patient education material was as follows: FRES 50.9 (standard error [SE]: 3.0), and FKGL, GFS, SI, CLI, and ARI all with scores ≥7. The mean readability for AUA patient material was as follows: FRES 64.0 (SE: 1.4), with all of FKGL, GFS, SI, and ARI scoring ≥7 readability. Only 13 out of 70 (18.6%) patient education materials' paragraphs met the readability requirements. The mean readability for bladder cancer patient education materials was the lowest, with a FRES of 36.7 (SE: 4.1).</p><p><strong>Conclusions and clinical implications: </strong>Patient education materials from leading urological associations reveal readability levels beyond the recommended thresholds for laypersons and may not be understood easily by patients. There is a future need for more patient-friendly reading materials.</p><p><strong>Patient summary: </strong>This study checked whether health information about different cancers was easy to read. Most of it was too hard for patients to understand.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1055-1061"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Alessandro Uleri, Jean Nicolas Cornu, Andrea Gobbo, et al. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.04.009. 关于Alessandro Uleri、Jean Nicolas Cornu、Andrea Gobbo 等:《5α-还原酶抑制剂与抑郁和自杀的关系》:小型系统回顾和元分析》。欧洲泌尿聚焦》。https://doi.org/10.1016/j.euf.2024.04.009.
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-14 DOI: 10.1016/j.euf.2024.06.013
David-Dan Nguyen, Naeem Bhojani, Quoc-Dien Trinh
{"title":"Re: Alessandro Uleri, Jean Nicolas Cornu, Andrea Gobbo, et al. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.04.009.","authors":"David-Dan Nguyen, Naeem Bhojani, Quoc-Dien Trinh","doi":"10.1016/j.euf.2024.06.013","DOIUrl":"10.1016/j.euf.2024.06.013","url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1066-1067"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Best Practice Guidelines for Collecting Microbiome Samples in Research Studies. 在研究中收集微生物组样本的最佳实践指南。
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2025-01-13 DOI: 10.1016/j.euf.2024.12.007
Ilaha Isali, Thomas R Wong, Shari Tian

Microbiome research has the potential to provide valuable information regarding the complex relationship between microbial communities and the human body. To help facilitate the translation of this potentially revolutionary research to clinical medicine, common guidelines and best practices are necessary. These guidelines should be based on the key findings of recent research in the field and address the primary areas of discrepancy in the previously published literature. Based on this review's findings, future microbiome research should adopt a consistent and clear approach to nomenclature, using standardized terminology to mitigate confusion. Additionally, only sample collection methods proven to reduce the risk of contamination should be utilized. While sample storage often creates difficulty in microbiome research, there are proven techniques that can improve results. With the wide array of research methodologies in the literature, standardization of metadata collection, kits, and analysis software could also be beneficial. Finally, documentation and records are critical in ensuring reproducibility, as is the case with all basic research. This brief review provides a foundation for evidence-based guidelines in microbiome research. PATIENT SUMMARY: This report outlines general guidelines and best practices for conducting microbiome research, which could significantly advance the field of medicine.

微生物组研究有可能为微生物群落与人体之间的复杂关系提供有价值的信息。为了帮助促进将这一潜在的革命性研究转化为临床医学,有必要制定共同的指导方针和最佳做法。这些指导方针应以该领域最近研究的主要发现为基础,并解决以前发表的文献中存在差异的主要领域。基于这篇综述的发现,未来的微生物组研究应该采用一致和明确的命名方法,使用标准化的术语来减少混淆。此外,只有经过证明可以降低污染风险的样品采集方法才能被使用。虽然样品储存经常给微生物组研究带来困难,但有一些经过验证的技术可以改善结果。有了文献中广泛的研究方法,元数据收集、工具包和分析软件的标准化也可能是有益的。最后,与所有基础研究一样,文件和记录对于确保可重复性至关重要。本文综述为微生物组研究的循证指南提供了基础。患者总结:本报告概述了进行微生物组研究的一般指导方针和最佳实践,这可能会显著推进医学领域。
{"title":"Best Practice Guidelines for Collecting Microbiome Samples in Research Studies.","authors":"Ilaha Isali, Thomas R Wong, Shari Tian","doi":"10.1016/j.euf.2024.12.007","DOIUrl":"10.1016/j.euf.2024.12.007","url":null,"abstract":"<p><p>Microbiome research has the potential to provide valuable information regarding the complex relationship between microbial communities and the human body. To help facilitate the translation of this potentially revolutionary research to clinical medicine, common guidelines and best practices are necessary. These guidelines should be based on the key findings of recent research in the field and address the primary areas of discrepancy in the previously published literature. Based on this review's findings, future microbiome research should adopt a consistent and clear approach to nomenclature, using standardized terminology to mitigate confusion. Additionally, only sample collection methods proven to reduce the risk of contamination should be utilized. While sample storage often creates difficulty in microbiome research, there are proven techniques that can improve results. With the wide array of research methodologies in the literature, standardization of metadata collection, kits, and analysis software could also be beneficial. Finally, documentation and records are critical in ensuring reproducibility, as is the case with all basic research. This brief review provides a foundation for evidence-based guidelines in microbiome research. PATIENT SUMMARY: This report outlines general guidelines and best practices for conducting microbiome research, which could significantly advance the field of medicine.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"909-913"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Human Urinary Microbiome and Its Potential Role in Urinary Tract Infections. 人类尿微生物组及其在尿路感染中的潜在作用。
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2025-01-17 DOI: 10.1016/j.euf.2024.12.005
Ceejay N Saenz, Michael L Neugent, Nicole J De Nisco

After identifying a urinary microbiota, new insights have emerged into how urinary tract infections (UTIs) develop and recur in women. This review explores factors influencing the urinary microbiome, and its role in UTI susceptibility and recurrence. Age, menopausal status, estrogen, and prior UTIs can impact the urinary microbiome significantly, with estrogen promoting predominance of beneficial Lactobacillus species in women. Study of the urinary microbiome has identified anaerobic bacteria as emerging uropathogens, as well as microbiome species that are markers of recurrent UTI susceptibility. UTIs also impact microbiome functions, including disrupting microbiome scaffolding sites (ie, glycosaminoglycans) and enriching antibiotic resistance genes. A clear link is becoming established between the natural flora of the human urinary tract and UTI susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome. PATIENT SUMMARY: A clear link is becoming established between the natural flora of the human urinary tract and urinary tract infection (UTI) susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome.

在确定了泌尿微生物群之后,关于女性尿路感染(uti)如何发展和复发的新见解已经出现。本文就泌尿系统微生物组的影响因素及其在尿路感染易感性和复发中的作用进行综述。年龄、绝经状态、雌激素和既往尿路感染可显著影响泌尿微生物群,其中雌激素促进有益乳杆菌在女性中占优势。泌尿微生物组的研究已经确定厌氧菌是新兴的泌尿病原体,以及微生物组物种是复发性尿路感染易感性的标志。uti还会影响微生物组的功能,包括破坏微生物组支架位点(即糖胺聚糖)和丰富抗生素耐药基因。人类尿路自然菌群与尿路感染易感性之间的明确联系正在建立,这也受到年龄和更年期过渡的影响。深化这一认识可以导致新一代尿路感染治疗和预防策略的发展,旨在调节尿微生物组。患者总结:人类尿路自然菌群与尿路感染(UTI)易感性之间的明确联系正在建立,这也受到年龄和更年期过渡的影响。深化这一认识可以导致新一代尿路感染治疗和预防策略的发展,旨在调节尿微生物组。
{"title":"The Human Urinary Microbiome and Its Potential Role in Urinary Tract Infections.","authors":"Ceejay N Saenz, Michael L Neugent, Nicole J De Nisco","doi":"10.1016/j.euf.2024.12.005","DOIUrl":"10.1016/j.euf.2024.12.005","url":null,"abstract":"<p><p>After identifying a urinary microbiota, new insights have emerged into how urinary tract infections (UTIs) develop and recur in women. This review explores factors influencing the urinary microbiome, and its role in UTI susceptibility and recurrence. Age, menopausal status, estrogen, and prior UTIs can impact the urinary microbiome significantly, with estrogen promoting predominance of beneficial Lactobacillus species in women. Study of the urinary microbiome has identified anaerobic bacteria as emerging uropathogens, as well as microbiome species that are markers of recurrent UTI susceptibility. UTIs also impact microbiome functions, including disrupting microbiome scaffolding sites (ie, glycosaminoglycans) and enriching antibiotic resistance genes. A clear link is becoming established between the natural flora of the human urinary tract and UTI susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome. PATIENT SUMMARY: A clear link is becoming established between the natural flora of the human urinary tract and urinary tract infection (UTI) susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"889-892"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism of Nephrolithiasis: Does the Microbiome Play a Role? 肾结石的发生机制:微生物群是否起作用?
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1016/j.euf.2024.11.010
Jose Agudelo, Sromona Mukherjee, Mangesh Suryavanshi, Bernardita Ljubetic, Marcelo Mass Lindenbaum, Aaron W Miller

Nephrolithiasis imposes a significant health care burden around the world. In the past decade, there has been considerable interest in the human microbiota in relation to the onset of nephrolithiasis. Most of the research has focused on degradation of oxalate, a known causative factor for nephrolithiasis, by bacteria in the gut. More recently, the role of antibiotic exposure and changes to short-chain fatty acids have been investigated. Studies have revealed that the urinary tract, previously thought to be sterile, harbors resident microbial communities closely associated with nephrolithiasis. In this mini-review, we evaluate potential causative roles of the microbiome in the onset of nephrolithiasis and the development of novel therapies to prevent this disease. PATIENT SUMMARY: This mini-review discusses scientific evidence on the influence of bacteria in our intestines and urinary tract on the formation of kidney stones. We discuss possible therapies targeting these bacteria that could prevent kidney stones from forming.

肾结石在世界各地造成了重大的卫生保健负担。在过去的十年中,人们对人类微生物群与肾结石发病的关系产生了相当大的兴趣。大多数研究都集中在肠道细菌对草酸盐的降解上,草酸盐是肾结石的已知致病因素。最近,抗生素暴露的作用和短链脂肪酸的变化已经被研究。研究表明,泌尿道,以前被认为是无菌的,窝藏着与肾结石密切相关的常驻微生物群落。在这篇小型综述中,我们评估了微生物群在肾结石发病中的潜在致病作用,以及预防这种疾病的新疗法的发展。患者总结:这篇小型综述讨论了肠道和泌尿道中细菌对肾结石形成影响的科学证据。我们讨论了针对这些细菌的可能的治疗方法,可以防止肾结石的形成。
{"title":"Mechanism of Nephrolithiasis: Does the Microbiome Play a Role?","authors":"Jose Agudelo, Sromona Mukherjee, Mangesh Suryavanshi, Bernardita Ljubetic, Marcelo Mass Lindenbaum, Aaron W Miller","doi":"10.1016/j.euf.2024.11.010","DOIUrl":"10.1016/j.euf.2024.11.010","url":null,"abstract":"<p><p>Nephrolithiasis imposes a significant health care burden around the world. In the past decade, there has been considerable interest in the human microbiota in relation to the onset of nephrolithiasis. Most of the research has focused on degradation of oxalate, a known causative factor for nephrolithiasis, by bacteria in the gut. More recently, the role of antibiotic exposure and changes to short-chain fatty acids have been investigated. Studies have revealed that the urinary tract, previously thought to be sterile, harbors resident microbial communities closely associated with nephrolithiasis. In this mini-review, we evaluate potential causative roles of the microbiome in the onset of nephrolithiasis and the development of novel therapies to prevent this disease. PATIENT SUMMARY: This mini-review discusses scientific evidence on the influence of bacteria in our intestines and urinary tract on the formation of kidney stones. We discuss possible therapies targeting these bacteria that could prevent kidney stones from forming.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"902-905"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Eileen V. Johnson, Kelsie Kaiser. Clinical Consultation Guide: Pelvic Floor Prehabilitation. Eur Urol Focus 2024;10:13-5. 回复:Eileen V. Johnson, Kelsie Kaiser:Eileen V. Johnson, Kelsie Kaiser.临床咨询指南:盆底预康复。Eur Urol Focus 2024;10:13-5.
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-20 DOI: 10.1016/j.euf.2024.05.026
Manuela Tutolo, Donatella Giraudo, Francesco Montorsi
{"title":"Re: Eileen V. Johnson, Kelsie Kaiser. Clinical Consultation Guide: Pelvic Floor Prehabilitation. Eur Urol Focus 2024;10:13-5.","authors":"Manuela Tutolo, Donatella Giraudo, Francesco Montorsi","doi":"10.1016/j.euf.2024.05.026","DOIUrl":"10.1016/j.euf.2024.05.026","url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1064-1065"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suprapubic Transvesical Adenoma Resection of the Prostate (STAR-P): A Novel Technique for Surgical Treatment of Benign Prostatic Hyperplasia. 耻骨上经膀胱前列腺腺瘤切除术(STAR-P):手术治疗良性前列腺增生的新技术。
IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-05 DOI: 10.1016/j.euf.2024.05.009
Bruno Bucca, Luca M Gobbi, Orietta Dalpiaz, Vincenzo Asero, Carlo M Scornajenghi, Federico Alviani, Leslie Claire Licari, Eugenio Bologna, Christian Gozzi

Background and objective: Several minimally invasive treatments have been developed to treat benign prostatic obstruction (BPO) via a transurethral approach, with a non-negligible risk of complications such as urethral stricture and external sphincter damage. Our aim was to present the Gozzi surgical technique for suprapubic transvesical adenoma resection of the prostate (STAR-P) for BPO and to assess its safety, feasibility, and outcomes.

Methods: We conducted a retrospective analysis of 44 consecutive patients who underwent STAR-P for BPO. All the procedures were performed in a single private hospital by one surgeon from 2020 to 2022. An innovative resectoscope designed by the surgeon was subsequently produced by Tontarra Medizintechnik (Wurmlingen, Germany) with a 42.06 Fr external sheath that allows the use of loops of three different sizes. The instrument is inserted into the bladder via suprapubic access, which ensures greater freedom of movement without compromising the external sphincter. Clinical data were retrospectively collected. Preoperative and intraoperative variables, postoperative complications, and functional outcomes of the STAR-P procedure were assessed. A descriptive statistical analysis was performed.

Key findings and limitations: No intraoperative complications were observed. Two patients (4.5%) experienced urinary urgency symptoms after catheter removal that resolved within 90 d. Median times were 105 min for surgery overall and 65 min for resection. All patients showed an improvement in voiding quality.

Conclusions and clinical implications: STAR-P is a safe, feasible, and cost-effective procedure that spares the bulbomembranous and penile urethra and the external urethral sphincter, and should be discussed with patients as a possible option for treatment of BPO.

Patient summary: We describe a new, safe, and feasible technique for surgical treatment of urinary obstruction caused by a large prostate. Keyhole surgery is performed through the lower abdomen, which means that the urethra below the prostate is not damaged. Only a small scar of 2-3 cm in the lower abdomen is evident at the end of the healing process.

背景和目的:经尿道治疗良性前列腺梗阻(BPO)的微创疗法层出不穷,但出现尿道狭窄和外括约肌损伤等并发症的风险不容忽视。我们的目的是介绍用于 BPO 的耻骨上经膀胱前列腺腺瘤切除术(STAR-P)的 Gozzi 手术技术,并评估其安全性、可行性和效果:我们对 44 例连续接受 STAR-P 治疗的 BPO 患者进行了回顾性分析。所有手术均由一名外科医生于 2020 年至 2022 年在一家私立医院完成。由外科医生设计的创新切除镜随后由 Tontarra Medizintechnik 公司(德国沃姆林根)生产,其外部鞘长 42.06 Fr,可使用三种不同尺寸的环。该器械通过耻骨上入路插入膀胱,确保了更大的活动自由度,同时又不影响外括约肌。对临床数据进行了回顾性收集。对术前和术中变量、术后并发症以及 STAR-P 手术的功能效果进行了评估。进行了描述性统计分析:未观察到术中并发症。两名患者(4.5%)在拔除导尿管后出现尿急症状,但在90天内缓解。手术总时间中位数为105分钟,切除时间中位数为65分钟。所有患者的排尿质量都有所改善:STAR-P是一种安全、可行且具有成本效益的手术,可保留球部尿道、阴茎尿道和尿道外括约肌,应与患者讨论,将其作为治疗BPO的一种可能选择。通过下腹部进行锁孔手术,这意味着不会损伤前列腺下方的尿道。愈合后,下腹部仅留下 2-3 厘米的小疤痕。
{"title":"Suprapubic Transvesical Adenoma Resection of the Prostate (STAR-P): A Novel Technique for Surgical Treatment of Benign Prostatic Hyperplasia.","authors":"Bruno Bucca, Luca M Gobbi, Orietta Dalpiaz, Vincenzo Asero, Carlo M Scornajenghi, Federico Alviani, Leslie Claire Licari, Eugenio Bologna, Christian Gozzi","doi":"10.1016/j.euf.2024.05.009","DOIUrl":"10.1016/j.euf.2024.05.009","url":null,"abstract":"<p><strong>Background and objective: </strong>Several minimally invasive treatments have been developed to treat benign prostatic obstruction (BPO) via a transurethral approach, with a non-negligible risk of complications such as urethral stricture and external sphincter damage. Our aim was to present the Gozzi surgical technique for suprapubic transvesical adenoma resection of the prostate (STAR-P) for BPO and to assess its safety, feasibility, and outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 44 consecutive patients who underwent STAR-P for BPO. All the procedures were performed in a single private hospital by one surgeon from 2020 to 2022. An innovative resectoscope designed by the surgeon was subsequently produced by Tontarra Medizintechnik (Wurmlingen, Germany) with a 42.06 Fr external sheath that allows the use of loops of three different sizes. The instrument is inserted into the bladder via suprapubic access, which ensures greater freedom of movement without compromising the external sphincter. Clinical data were retrospectively collected. Preoperative and intraoperative variables, postoperative complications, and functional outcomes of the STAR-P procedure were assessed. A descriptive statistical analysis was performed.</p><p><strong>Key findings and limitations: </strong>No intraoperative complications were observed. Two patients (4.5%) experienced urinary urgency symptoms after catheter removal that resolved within 90 d. Median times were 105 min for surgery overall and 65 min for resection. All patients showed an improvement in voiding quality.</p><p><strong>Conclusions and clinical implications: </strong>STAR-P is a safe, feasible, and cost-effective procedure that spares the bulbomembranous and penile urethra and the external urethral sphincter, and should be discussed with patients as a possible option for treatment of BPO.</p><p><strong>Patient summary: </strong>We describe a new, safe, and feasible technique for surgical treatment of urinary obstruction caused by a large prostate. Keyhole surgery is performed through the lower abdomen, which means that the urethra below the prostate is not damaged. Only a small scar of 2-3 cm in the lower abdomen is evident at the end of the healing process.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"991-998"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European urology focus
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1